Acquisitions, Mergers & PartnershipsAM IndustryBioprinting

3D Systems continues push into bioprinting with Allevi deal

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

The research community is critical to developing breakthrough innovations in regenerative medicine. 3D Systems, with the addition of Allevi Inc, is now able to provide a robust set of Allevi by 3D Systems bioprinting solutions to researchers and industry giants in hundreds of labs globally.

Allevi is a leading innovator in the bioprinting space with an exclusive focus on the research and development community. Leading laboratories leverage Allevi’s portfolio of hardware, biomaterials and software to design, engineer and build solutions for tissue engineering, organ-on-a-chip research, pharmaceutical validation, biomaterial development, and regenerative medicine.

3D Systems pushes into bioprinting with Allevi by 3D Systems
3D bioprinted trachea model (Image courtesy of United Therapeutics)

Allevi desktop 3D bioprinters are among the most versatile, powerful and easy-to-use bioprinters on the market. Customers also have access to a wide range of biomaterials—bioinks, bioink additives, cells, reagents and consumables—as well as an intuitive software interface.

In the medical field, 3D Sytems has delivered additive manufacturing solutions to the healthcare community for more than 30 years. Having produced more than 2,000,000 serial component medical devices and 140,000 patient-specific surgical cases, the company is now scaling the production of bioprinted clinical applications. This technology will elevate patient care through various clinical applications ranging from acellular bioresorbable devices to functionalized solid organs for transplantation.

3D Systems pushes into bioprinting with Allevi by 3D Systems
3D Systems Print to Perfusion™ advanced technology development

Before bioprinter hardware manufacturer Allevi, 3D Systems had already entered the bioprinting services market. Together with United Therapeutics Corporation and its organ manufacturing and transplantation-focused subsidiary, Lung Biotechnology PBC, the company achieved significant progress in the development of next-generation bioprinting solutions for lung scaffolds that are capable of full size, vascularized, rapid, micron-level printing.

3D Systems’ capabilities as a technology innovator, spanning hardware, software, and materials science, combined with United Therapeutics’ renowned expertise in regenerative medicine has enabled advances in lung modeling, 3D printing, as well as material formulation and material handling to yield significant capabilities in bioprinters and biomaterials for the eventual production of transplantable organs.

The Allevi bioprinter.

To meet the evolving needs of the clinical and R&D communities, 3D Systems continues to push technologies to facilitate advanced application development. The Print to Perfusion process enables 3D printing of high-resolution scaffolds, which can be perfused with living cells to create tissues.

The ability to print large, vascularized, highly detailed hydrogel scaffolds at rapid speeds is opening new opportunities for a range of tissue applications. In addition, we are developing bioprinting solutions that are both commercially viable and scalable from prototype to production.

Research
Consumer Products AM 2024

This new market study from VoxelMatters provides an in-depth analysis and forecast of polymer and metal AM in the consumer products industry across the three core segments of the additive manufactu...

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Save
Accept all Services

Newsletter

Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.